Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
CV Sciences ( (CVSI) ) has provided an announcement.
On March 4, 2026, CV Sciences, Inc. entered into an agreement with an institutional investor to amend and restate two existing secured promissory notes with an aggregate principal now increased by 20% to $2,256,000. The amended notes add a conversion feature that allows the investor to convert principal into common stock at a fixed price of $0.06 per share, initially representing 37.6 million shares, subject to ownership caps to prevent the investor from exceeding specified beneficial ownership thresholds.
The restructuring eliminates the company’s previous obligation to make monthly redemptions before maturity and introduces a true-up provision designed to ensure the investor recoups the full principal through share conversions and sales, with the possibility of issuing an additional senior secured convertible note if proceeds fall short beyond a set threshold. Management presented the March 10, 2026 announcement as a significant milestone in its strategy to strengthen the balance sheet, enhance financial flexibility and support long-term growth, while concurrently highlighting the recent launch of Empowr, a plant-based protein and creatine product that expands its +PlusHLTH cannabinoid-free wellness line.
The most recent analyst rating on (CVSI) stock is a Sell with a $0.04 price target. To see the full list of analyst forecasts on CV Sciences stock, see the CVSI Stock Forecast page.
Spark’s Take on CVSI Stock
According to Spark, TipRanks’ AI Analyst, CVSI is a Neutral.
The score is held back primarily by weak fundamentals—sharp revenue contraction, ongoing losses, and thin/negative free cash flow—despite some margin improvement and manageable leverage. Technical indicators are neutral with modest positive momentum, but valuation remains unattractive due to negative earnings, and the latest company update highlights regulatory and demand pressures even as it pursues product launches and growth initiatives.
To see Spark’s full report on CVSI stock, click here.
More about CV Sciences
CV Sciences, Inc. is a consumer wellness company specializing in nutraceuticals and plant-based foods, offering hemp extracts and other science-backed natural ingredients and products across B2B and B2C channels. Its flagship +PlusCBD brand is a leading hemp-extract supplement in the U.S. natural products market, while its +PlusHLTH line and Cultured Foods and Elevated Softgels units broaden its cannabinoid-free supplements, contract manufacturing and plant-based foods footprint in the U.S. and Europe.
The company’s portfolio includes cannabinoid and cannabinoid-free formulations supported by clinical research and GRAS status, with distribution through select U.S. retailers and international markets. CV Sciences operates from facilities in San Diego, Grand Junction and Warsaw, positioning it as a diversified player in the wellness, nutraceutical and plant-based food sectors.
Average Trading Volume: 1,315,063
Technical Sentiment Signal: Buy
Current Market Cap: $10.13M
See more data about CVSI stock on TipRanks’ Stock Analysis page.